UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

Clinical cancer research, 2007-06, Vol.13 (11), p.3207-3214

2007

Volltextzugriff (PDF)

Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

Journal of clinical oncology, 2007-04, Vol.25 (10), p.1239-1246

2007

Volltextzugriff (PDF)

Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition

The New England journal of medicine, 2004-07, Vol.351 (5), p.427-437

2004

Volltextzugriff (PDF)

Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial

Journal of clinical oncology, 2007-09, Vol.25 (25), p.3859-3865

2007

Volltextzugriff (PDF)

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

The Lancet (British edition), 2002-06, Vol.359 (9324), p.2131-2139

2002

Volltextzugriff (PDF)

The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer

British journal of cancer, 1997-01, Vol.76 (4), p.486-493

1997

Volltextzugriff (PDF)

Cancer risks in BRCA2 families: estimates for sites other than breast and ovary

Journal of medical genetics, 2005-09, Vol.42 (9), p.711-719

2005

Volltextzugriff (PDF)

Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation

The New England journal of medicine, 2001-07, Vol.345 (3), p.159-164

2001

Volltextzugriff (PDF)

Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study

International journal of radiation oncology, biology, physics, 2006-03, Vol.64 (4), p.1081-1091

2006

Volltextzugriff (PDF)

Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling

Journal of clinical oncology, 2005-02, Vol.23 (4), p.732-740

2005

Volltextzugriff (PDF)

RNA Expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response

Clinical cancer research, 2003-02, Vol.9 (2), p.827-836

2003

Volltextzugriff (PDF)

CHEK21100delC and Susceptibility to Breast Cancer: A Collaborative Analysis Involving 10,860 Breast Cancer Cases and 9,065 Controls from 10 Studies

American journal of human genetics, 2004-06, Vol.74 (6), p.1175-1182

2004

Volltextzugriff (PDF)

Long-Term Psychological Impact of Carrying a BRCA1/2 Mutation and Prophylactic Surgery: A 5-Year Follow-Up Study

Journal of clinical oncology, 2003-10, Vol.21 (20), p.3867-3874

2003

Volltextzugriff (PDF)

Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients

JNCI : Journal of the National Cancer Institute, 2002-01, Vol.94 (2), p.116-128

2002

Volltextzugriff (PDF)

Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized Trials

Journal of clinical oncology, 2001-01, Vol.19 (2), p.343-353

2001

Volltextzugriff (PDF)

Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over

Journal of clinical oncology, 2000-02, Vol.18 (4), p.724-733

2000

Volltextzugriff (PDF)

Survival and prognostic factors in BRCA1-associated breast cancer

Annals of oncology, 2006-03, Vol.17 (3), p.391-400

2006

Volltextzugriff (PDF)

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424)

Cancer research (Chicago, Ill.), 2002-08, Vol.62 (16), p.4617-4622

2002

Volltextzugriff (PDF)

Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer

Cancer research (Chicago, Ill.), 2005-05, Vol.65 (10), p.4101-4107

2005

Volltextzugriff (PDF)

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer

Cancer research (Chicago, Ill.), 2001-07, Vol.61 (14), p.5407-5414

2001

Volltextzugriff (PDF)

Combined Treatment With Buserelin and Tamoxifen in Premenopausal Metastatic Breast Cancer: a Randomized Study

JNCI : Journal of the National Cancer Institute, 2000-06, Vol.92 (11), p.903-911

2000

Volltextzugriff (PDF)

The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients

Cancer research (Chicago, Ill.), 2000-02, Vol.60 (3), p.636-643

2000

Volltextzugriff (PDF)

Effectiveness of Breast Cancer Surveillance in BRCA1/2 Gene Mutation Carriers and Women With High Familial Risk

Journal of clinical oncology, 2001-02, Vol.19 (4), p.924-930

2001

Volltextzugriff (PDF)

Which Cyclin E Prevails as Prognostic Marker for Breast Cancer? Results from a Retrospective Study Involving 635 Lymph Node–Negative Breast Cancer Patients

Clinical cancer research, 2006-06, Vol.12 (11), p.3319-3328

2006

Volltextzugriff (PDF)

Laser microdissection and microarray analysis of breast tumors reveal ER-α related genes and pathways

Oncogene, 2006-03, Vol.25 (9), p.1413-1419

2006

Volltextzugriff (PDF)

1 – 25 von 243

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(226)
Mit Volltextzugriff
(217)

Publikationsform

Artikel
(241)
Tagungsberichte
(2)

Sprache

Englisch
(243)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition

Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer

Cancer risks in BRCA2 families: estimates for sites other than breast and ovary

Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation

Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study

Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling

RNA Expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response

CHEK21100delC and Susceptibility to Breast Cancer: A Collaborative Analysis Involving 10,860 Breast Cancer Cases and 9,065 Controls from 10 Studies

Long-Term Psychological Impact of Carrying a BRCA1/2 Mutation and Prophylactic Surgery: A 5-Year Follow-Up Study

Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients

Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized Trials

Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over

Survival and prognostic factors in BRCA1-associated breast cancer

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424)

Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer

Combined Treatment With Buserelin and Tamoxifen in Premenopausal Metastatic Breast Cancer: a Randomized Study

The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients

Effectiveness of Breast Cancer Surveillance in BRCA1/2 Gene Mutation Carriers and Women With High Familial Risk

Which Cyclin E Prevails as Prognostic Marker for Breast Cancer? Results from a Retrospective Study Involving 635 Lymph Node–Negative Breast Cancer Patients

Laser microdissection and microarray analysis of breast tumors reveal ER-α related genes and pathways

Suchergebnisse filtern